Showing results (221-230 of 259) with videos related to
Sort By:
Pageof 26
Communications Biology|November 5, 2020
De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitorsSamuel T Workenhe, Andrew Nguyen, David Bakhshinyan, et al.Nature Communications|May 16, 2018
Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinomaJeffrey P North, Justin Golovato, Charles J Vaske, et al.Cancer Immunology Research|September 16, 2017
Customized Viral Immunotherapy for HPV-Associated CancerMatthew J Atherton, Kyle B Stephenson, Jonathan Pol, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.Cancer Immunology Research|July 12, 2019
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial ImmunotherapyKarin L Lee, Stephen C Benz, Kristin C Hicks, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Utility of <sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on <sup>68</sup>Ga-PSMA-11 PET/CTSherrington Li, Andrew Nguyen, William Counter, et al.Therapeutic Advances in Medical Oncology|March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2025
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective StudyVishnu Murthy, Koichiro Kimura, Lela Theus, et al.European Urology Oncology|August 8, 2020
Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)Megan Crumbaker, Sarennya Pathmanandavel, Andrew O Yam, et al.JACC. Heart Failure|November 9, 2023
Impact of Digital Health Technology on Quality of Life in Patients With Heart FailureAngela M Victoria-Castro, Melissa L Martin, Yu Yamamoto, et al.Pageof 26